Cannabis use disorder pharmacotherapy programs reach late-stage trials
Late-stage cannabis use disorder pharmacotherapy programs and integrated behavioural-and-pharmacological care models are emerging in a previously bare category.
Cannabis use disorder has been a behavioural-therapy-only category with no approved pharmacotherapy. Late-stage programs targeting cannabinoid pathway and adjacent mechanisms are now reading out, integrated behavioural-and-pharmacological care models are emerging, and structured screening in primary care is becoming more common. The category may acquire its first specifically-approved pharmacotherapy in the next 24 to 36 months.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.